Concepedia

David Agorku

DA

8

Publications

343

Citations

8

H-Index

2015

Active since

Affiliations

Miltenyi Biotec (Germany)(Current)

Universitätsmedizin Göttingen

University Hospital Heidelberg

Heidelberg Institute for Stem Cell Technology and Experimental Medicine

Progenity (United States)

David Agorku is an author at Miltenyi Biotec (Germany) specializing in oncology, tumor microenvironment, and tumor biology.

ORCID

Top concepts

Publications per year

2015–2024

8

Publications

8

Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma

Daniel Schäfer, Stefan Tomiuk, Laura N. Küster et al. · Nature Communications · 2021 · 82 citations · Full text

The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features

Andrea Aloia, Evgeniya Petrova, Stefan Tomiuk et al. · Breast Cancer Research · 2015 · 81 citations · Full text

Identification, isolation and characterization of human LGR5-positive colon adenoma cells

Michael K. Dame, Durga Attili, Shannon D. McClintock et al. · Development · 2018 · 72 citations · Full text

CD49b, CD87, and CD95 Are Markers for Activated Cancer-Associated Fibroblasts Whereas CD39 Marks Quiescent Normal Fibroblasts in Murine Tumor Models

David Agorku, Anne Langhammer, Ute Heider et al. · Frontiers in Oncology · 2019 · 33 citations · Full text

, , +14

Colorectal cancer-associated fibroblasts inhibit effector T cells via NECTIN2 signaling

David Agorku, Andreas Bosio, Frauke Alves et al. · Cancer Letters · 2024 · 23 citations · Full text

, , +13

Rows per page

1–5 of 8